Clinical Trial Update: Comparative Clinical Trial to Evaluate Efficacy, Safety and Tolerance of BCD-054 and Avonex® for Treatment of Patients With Remitting-relapsing Multiple Sclerosis [Phase 2, Phase 3]

View source ↗

Summary

Phase 2/3 trial comparing BCD-054 with Avonex for relapsing-remitting multiple sclerosis has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Sclerosis Relapsing-remitting

Drugs mentioned

• Avonex (Interferon beta-1a)
• BCD-054 (Pegylated Interferon Beta-1a)

Snippet

Sponsor: Biocad | Conditions: Multiple Sclerosis, Relapsing-Remitting | Phase 2, Phase 3 | Status: COMPLETED